Black Diamond Therapeutics (BDTX) Liabilities and Shareholders Equity: 2018-2021
Historic Liabilities and Shareholders Equity for Black Diamond Therapeutics (BDTX) over the last 2 years, with Sep 2021 value amounting to $274.1 million.
- Black Diamond Therapeutics' Liabilities and Shareholders Equity fell 20.87% to $274.1 million in Q3 2021 from the same period last year, while for Sep 2021 it was $1.2 billion, marking a year-over-year decrease of 0.99%. This contributed to the annual value of $329.7 million for FY2020, which is 108.26% up from last year.
- Latest data reveals that Black Diamond Therapeutics reported Liabilities and Shareholders Equity of $274.1 million as of Q3 2021, which was down 4.78% from $287.9 million recorded in Q2 2021.
- In the past 5 years, Black Diamond Therapeutics' Liabilities and Shareholders Equity ranged from a high of $362.8 million in Q1 2020 and a low of $51.8 million during Q4 2018.
- Over the past 3 years, Black Diamond Therapeutics' median Liabilities and Shareholders Equity value was $321.5 million (recorded in 2020), while the average stood at $302.7 million.
- In the last 5 years, Black Diamond Therapeutics' Liabilities and Shareholders Equity skyrocketed by 205.44% in 2019 and then fell by 20.87% in 2021.
- Black Diamond Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $51.8 million in 2018, then soared by 205.44% to $158.3 million in 2019, then skyrocketed by 108.26% to $329.7 million in 2020, then fell by 20.87% to $274.1 million in 2021.
- Its Liabilities and Shareholders Equity stands at $274.1 million for Q3 2021, versus $287.9 million for Q2 2021 and $313.3 million for Q1 2021.